Stephanie Saw: Real-world evidence of adding pemetrexed-platinum chemotherapy upon osimertinib progression

Stephanie Saw, Medical Oncologist at National Cancer Center of Singapore, shared on X/Twitter:

“Just out in Lung Cancer Journal our RWE of adding pemetrexed-platinum chemotherapy upon osimertinib progression. Median TTF2 6.6m, combined TTF1+TTF2 23.4m, ORR 45.0% and intracranial control in 90.6%. L858R and CNS mets benefit too. Great collab Molly Li.”

Visit the article website.
Source: Stephanie Saw/X